middle.news
Recce Pharmaceuticals Secures $5.3M R&D Rebate and Advances U.S. Army Burn Wound Research
7:07pm on Thursday 30th of April, 2026 AEST
•
Healthcare
Read Story
Recce Pharmaceuticals Secures $5.3M R&D Rebate and Advances U.S. Army Burn Wound Research
7:07pm on Thursday 30th of April, 2026 AEST
Key Points
Received $5.3 million AUD R&D tax rebate for FY2025
Second CRADA signed with U.S. Army Institute of Surgical Research
Brazil patent granted protecting anti-infectives until 2041
Phase 3 diabetic foot infection trial dosing ongoing in Indonesia
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE